Omnicell OMCL Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | $19.92M+213% | $23.09M+211% | $21.18M+201% | ||
| $77.38M-4.4% | $78.81M-4.2% | $78.96M-6.0% | $79.76M-6.5% | $80.96M-6.5% | ||
| $43.21M+4.2% | $44.5M+13.2% | $41.57M-2.1% | $41.96M-8.5% | $41.46M-16.9% | ||
| —— | —— | —— | —— | -$14.08M— | ||
| $2.41M-32.1% | $2.65M-30.0% | $3.03M-27.5% | $3.31M-22.2% | $3.55M-17.8% | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| -$499K+52.5% | -$488K+50.1% | -$974K-11.4% | -$1.05M+41.7% | -$1.05M+42.0% | ||
| —— | —— | $12.14M+169% | $10.34M+133% | -$7.97M+78.8% | ||
| $5.96M— | -$9.28M— | $14.96M— | —— | —— | ||
| -$22.45M— | -$20.78M— | -$7.9M— | —— | —— | ||
| —— | —— | -$7.03M— | -$5.8M— | -$3.15M— | ||
| $1.7M— | $1.87M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $6.9M+4,057% | $7.77M+32,463% | $1.36M+49.5% | $6.81M+615% | $166K+112% | ||
| $7.92M+6.5% | $7.84M+4.2% | $8.11M+11.4% | $7.53M-4.9% | $7.44M-6.1% | ||
| —— | $0-100% | $1.88M-66.7% | $3.76M0.0% | $5.64M+200% | ||
| -$11.9M-10.5% | -$11.73M-9.2% | -$11.47M-6.3% | -$11.06M-0.2% | -$10.76M+2.3% | ||
| —— | —— | $9.05M+75,550% | $1.06M-38.8% | -$5.01M-184% | ||
| —— | —— | —— | -$9.96M+70.3% | $2.85M+104% | ||
| $155.88M-4.8% | $127.3M-32.2% | $153.26M-9.8% | $147.75M-27.6% | $163.69M-25.0% | ||
| $41.68M+7.8% | $40.42M+10.8% | $41.79M+14.7% | $40.91M+7.1% | $38.68M-4.0% | ||
| -$60.49M-7.7% | -$60.36M-14.3% | -$59.51M-15.3% | -$58.57M-11.7% | -$56.19M-4.6% | ||
| $16.36M+20.0% | $16.87M+25.8% | $15.43M+15.9% | $13.54M-16.2% | $13.64M-28.8% | ||
| $7.9M+21.2% | $7.68M+59.2% | $7.25M+51.6% | $6.89M+32.7% | $6.51M-2.8% | ||
| -$229.06M+7.3% | -$227.41M+4.9% | -$461.84M-5,580% | -$241.86M-2,249% | -$247.02M-885% | ||
| $1.19M+194% | $3.85M+324% | $705K+6,509% | $2.39M+204% | $405K+119% | ||
| —— | —— | -$367.44M-382% | -$146.74M-191% | -$135.56M-170% | ||
| $2.41M-32.1% | $2.65M-30.0% | $3.03M-27.5% | $3.31M-22.2% | $3.55M-17.8% | ||
| -$499K+52.5% | -$488K+50.1% | -$974K-11.4% | -$1.05M+41.7% | -$1.05M+42.0% | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| —— | $599K— | $449.25K— | $299.5K— | $149.75K— | ||
| —— | —— | —— | -$9.96M+70.3% | $2.85M+104% | ||
| —— | —— | —— | —— | $4.6M— | ||
| $7.49M-23.5% | $10.17M-7.5% | $5.44M-43.5% | $4.31M-74.3% | $9.79M-19.4% | ||
| -$11.9M-10.5% | -$11.73M-9.2% | -$11.47M-6.3% | -$11.06M-0.2% | -$10.76M+2.3% | ||
| —— | —— | $9.05M+75,550% | $1.06M-38.8% | -$5.01M-184% | ||
| $1.7M— | $1.87M— | —— | —— | —— | ||
| —— | —— | —— | $2M+141% | $7.57M+213% | ||
| $6.9M+4,057% | $7.77M+32,463% | $1.36M+49.5% | $6.81M+615% | $166K+112% | ||
| $7.92M+6.5% | $7.84M+4.2% | $8.11M+11.4% | $7.53M-4.9% | $7.44M-6.1% | ||
| —— | $2.43M— | $1.82M— | $1.22M— | $607.5K— | ||
| $16.38M-6.5% | $17.52M+7.3% | $17.72M+16.9% | $17.66M+24.0% | $17.51M+30.4% | ||
| —— | $0-100% | $97.75M-66.7% | $195.5M0.0% | $293.25M+200% | ||
| —— | $0-100% | $181.75K-66.7% | $363.5K0.0% | $545.25K+200% | ||
| $16.36M+20.0% | $16.87M+25.8% | $15.43M+15.9% | $13.54M-16.2% | $13.64M-28.8% | ||
| $24.17M— | $25.1M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$11.9M-10.5% | -$11.73M-9.2% | -$11.47M-6.3% | -$11.06M-0.2% | -$10.76M+2.3% | ||
| $114.2M-8.7% | $86.89M-42.6% | $111.47M-16.4% | $106.84M-35.6% | $125.02M-29.8% | ||
| $114.2M-8.7% | $86.89M-42.6% | $111.47M-16.4% | $106.84M-35.6% | $125.02M-29.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Omnicell generate?
- Omnicell (OMCL) generated $155.9M in operating cash flow over the trailing twelve months.
- What is Omnicell's free cash flow?
- After $41.7M of capital expenditures, Omnicell's free cash flow was $114.2M over the trailing twelve months, down 8.6% year over year.
- Where does Omnicell's cash flow data come from?
- Every line is extracted from Omnicell's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
